期刊文献+

甲磺酸帕珠沙星即型凝胶滴眼剂的制备及质量控制 被引量:2

Preparation and quality control of in-situ gelling of pazufloxacin mesilte eye drops
原文传递
导出
摘要 目的探讨甲磺酸帕珠沙星即型凝胶滴眼剂(0.3%)的制备及含量测定方法。方法以硼酸为渗透压调节剂,海藻酸钠为增稠剂,制备甲磺酸帕珠沙星即型凝胶滴眼剂(0.3%)。用高效液相色谱法测定含量。结果甲磺酸帕殊沙星检测浓度在4—40μg/ml范围内与峰面积分值线性关系良好,t=0.0005,平均回收率为(99.985±0.205)%。RSD为0.322%。本品渗透压为320m0sm/kg,pH值为4.87。家兔眼刺激性实验表明,该滴眼剂对家兔眼睛无刺激性,符合中国药典滴眼剂的要求。结论本滴眼剂处方工艺简单,质量容易控制,稳定性良好。 objective To establish a method fbr preparation and measuring the content of pazufloxaxin mesilate in the in - situ gelling of eye drops(0.3% ). Methods In this study, in - situ gelling of pazufloxacin mesilate eye drops took boric acid as buffer to regulate the pH and osmotic pressure. The sustained - release eye drops using sodium alginate as viscosity - promoting agent was studied. The uhraviolet speetrophtonetric method was established for the determination of pazufloxacin mesilate. Results There was a good linear relationship within the concentration range of 4 -40 μg/ml. The average recovery of pazuloxacin mesilate was 99. 85 +-0. 205. The RSD was 0.322%. The osmotic pressure and pH of the solution were 320 mOsm/kg and 4.87 respeetively. The result of rabbit - eye irritation test showed that the eye drops had no irritation. Conclusison The pazufloxacin mesilate in - situ gelling of eye drops is promising with simple fnrmula, preparation process, easy quality and stability.
作者 修佳
机构地区 河南省人民医院
出处 《临床医学》 CAS 2008年第8期108-110,共3页 Clinical Medicine
关键词 甲磺酸帕珠沙星 即型凝胶 滴眼剂 Pazufloxacin mesilatc In - situ gelling Eye drops
  • 相关文献

参考文献6

二级参考文献62

共引文献116

同被引文献34

  • 1代龙.离子敏感型即型凝胶的研究进展[J].中国中药杂志,2009,34(5):515-518. 被引量:6
  • 2王志钢,王艳姣,李慧,臧琛,张保献.丹葛明目即型凝胶的制备研究[J].中国中药杂志,2012,37(1):46-51. 被引量:14
  • 3高斐,王东凯,罗立,徐松林,刘莱,徐飒.左氧氟沙星热敏型眼用凝胶的研制及体外释放研究[J].中国药房,2005,16(14):1057-1059. 被引量:42
  • 4贾东明,蔺胜照,薛胜霞.国外即型水凝胶——温度敏感系统综述[J].中国医院药学杂志,2007,27(4):523-526. 被引量:1
  • 5Ramesh C, Nagarwal, Shri Kant, et al. Polymeric nanoparticulate system : A potential approach for ocular drug delivery[J]. Journal of Controlled Release, 2009,136 ( 1 ) : 2-13.
  • 6Maria de la Fuente, Manuela Ravina, Patrizia Paolicelli, et al. Chi- tosan-based nanostructures :A delivery plafforul for ocular thera- peutics[J]. Advanced Drug Delivery Reviews ,2010,62(1 ) : 100-117.
  • 7Roberta Cavalli, M Rosa Gasco, Patrizia Chetoni, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin[J]. In- ternational Joumal of Pharmaceutics ,2002,238(1-2) : 241-245.
  • 8Wen-Di Ma, Hui Xu, Chao Wang, et al. Pluronie F127-g-poly (acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system [J]. International Journal of Pharmaceutics, 2008, 350(1-2): 247-256.
  • 9Lee SS, Hughes P, Ross AD, et al. Biodegradable Implants for Sus- tained Drug Release in the Eye[J]. Pharm Res, 2010,27 (10) : 2045- 2053.
  • 10Thrimawithana, TR, Young, S, Bunt, CR, et al. Drug delivery to the posterior segment of the eye[J]. Drug Discovery Today, 2011, 16 (5-6) : 270-277.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部